コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
5 ed by the competitive inhibitor reserpine, a second-line agent to treat hypertension, and by the nonc
10 nt-to-treat population, 414 (69.9%) received second-line and 256 (43.2%) received third-line therapy.
15 es (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples.
16 pilepticus, rather than additional trials of second-line anti-epileptic drugs, to avoid neuronal inju
19 ciency virus (HIV)-infected children failing second-line antiretroviral therapy (ART) have no access
24 that reduces the efficacy of ethionamide, a second-line antitubercular drug used to combat multidrug
25 utations to predict resistance to first- and second-line antituberculosis drugs and validated our pre
29 constructed a cohort of patients switched to second-line ART (1 January 2003 through 31 December 2008
31 2.6, 95% CI 2.5-2.8; p<0.0001) and switch to second-line ART (HR 5.2, 4.4-6.1; p<0.0001]) compared wi
34 e drug levels were at higher risk of failing second-line ART and thus should be closely monitored.
36 use mortality, new AIDS events and switch to second-line ART due to presumed treatment failure, using
37 5 eligible patients, 10,352 (3%) switched to second-line ART during 782 ,412 person-years of follow-u
39 the randomised open-label SECOND-LINE trial, second-line ART NtRTI selection was made by either genot
44 nitiating protease inhibitor (PI)-containing second-line ART within the Program for HIV Prevention an
56 Little is known about the drug survival of second-line biologic therapies for psoriasis in routine
57 pport clinical decision making when choosing second-line biologic therapy for patients with psoriasis
58 Area and Severity Index at switching to the second-line biologic therapy were predictors of overall
59 -based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this po
60 emoglobin </= 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, w
63 ide reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in
66 biologic therapies and decreased over time; second-line discontinuation because of adverse events wa
70 re ineligible for the new regimen because of second-line drug resistance, we projected a change in in
79 (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as wel
80 ST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcomes in patients wi
84 -tuberculosis patients, only 44.7% (596) had second-line DST for both fluoroquinolones and second-lin
91 e III study reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the
92 mucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irino
93 weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concen
94 state cancer, with no more than two previous second-line hormonal therapies, and a castrate concentra
98 However, guidelines have neither addressed second-line hormonal therapy for nonmetastatic CRPC nor
99 fliximab and adalimumab can be considered as second-line immunomodulatory agents for the treatment of
102 lgesic (49.1% of patients); opiates are the "second line" in 31.5% of patients; however, 33% patients
104 -for-age z score < -2 standard deviations at second-line initiation (aHR, 2.8; P = .03), and undetect
106 nge [IQR], 1.4-3.3 years), and median age at second-line initiation was 10.7 years (IQR, 6.3-13.4 yea
109 least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for a
110 ST results for at least fluoroquinolones and second-line injectable drugs, and not having extensively
111 oroquinolone-resistant multidrug resistance, second-line injectable-resistant multidrug resistance, a
112 econd-line DST for both fluoroquinolones and second-line injectable: 55.8% (466 of 835) in the Wester
113 mycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Hea
115 cond-line IPI or first-line NIVO followed by second-line IPI are the most cost-effective, immune-base
116 ma, first-line PEM every 3 weeks followed by second-line IPI or first-line NIVO followed by second-li
119 for patients with multiple ART failures; (2) second-line LA-ART for those failing first-line therapy;
120 e analysis; 32% received T-DM1 as first- and second-line line therapy, and 48% received it as fourth-
121 nce supports alternatives to splenectomy for second-line management of patients with persistently low
123 Epinephrine is life-saving in anaphylaxis; second-line medications (including antihistamines and gl
126 s in patients with CRPC receiving first- and second-line NHT and, to the best of our knowledge, is th
127 ohort (and separately for the first-line and second-line NHT cohorts) were best for CTC- patients, in
132 hods because of progression of disease after second-line OAC, particularly if vitreous seeds are pres
133 ay epithelial basal cells, which serves as a second line of airway epithelial defense that is induced
134 In addition, Tyr-92 was identified as a second line of defense to maintain the position of Phe-1
136 llow up, 106 (4.1%) participants switched to second-line, of whom 18 (17.0%) switched with VL < 1000
138 d rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in pati
140 ol-defined population (patients who received second-line or later treatment); safety was also assesse
141 stigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with adv
142 this randomised trial, vorinostat given as a second-line or third-line therapy did not improve overal
143 to investigate whether vorinostat given as a second-line or third-line therapy improved patients' ove
145 tries and randomly assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or place
150 tor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-li
155 nd middle-income countries increasingly need second-line regimens with boosted protease inhibitors.
156 motherapy in the neoadjuvant and adjuvant or second-line setting compared with more widely adopted re
158 ials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized tria
163 s studied in urothelial carcinoma are in the second-line setting; new targets include CD105, polo-lik
164 emental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer tre
166 of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overal
168 sed study, we analysed patients who received second-line targeted therapy for metastatic renal cell c
170 Median overall survival since the start of second-line targeted therapy was 12.5 months (95% CI 11.
175 high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who
176 involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, an
182 by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients
184 s, VEGF receptors, PDGFR-beta, and c-KIT, as second-line therapy both in patients with FGFR2-mutated
185 ment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC).
186 etinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC.
187 r receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma
188 reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence
191 wo hundred patients potentially eligible for second-line therapy had a PSS of 5.3 (4.6-7.1) months, w
193 l survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients
194 observed therapy would improve outcomes with second-line therapy in HIV-infected patients for whom fi
195 Hypoglossal nerve stimulation is a useful second-line therapy in patients who cannot tolerate cont
197 maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic
201 b could be considered a standard of care for second-line therapy in this post-hydroxyurea patient pop
203 pean centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in
204 , had a shorter survival after initiation of second-line therapy on univariate, but not on multivaria
207 % CI, 0.55 to 0.88; P = .0021) from start of second-line therapy were longer in patients in arm A com
208 hree hundred three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57
209 rapy (with at least a partial response after second-line therapy); had received a purine analogue, be
215 subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus c
216 When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologi
233 ore effective than either alone and provides second line treatment for those with rhinitis poorly con
235 rognostic factor for treatment failure after second-line treatment (HR, 1.2 per 10 years; 95% CI, 1.2
236 or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation
239 al photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus
240 oint blockers have recently been approved as second-line treatment for advanced non-small-cell lung c
241 nib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer.
242 tment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistanc
243 xel, and could be regarded as a new standard second-line treatment for patients with advanced gastric
244 versible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamou
245 rvival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic color
246 nation with paclitaxel could be an effective second-line treatment for patients with platinum-pretrea
247 al impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursode
248 ment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.
251 l photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because i
252 -receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP).
254 vatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal
255 ty of afatinib compared with methotrexate as second-line treatment in patients with recurrent or meta
256 pective cohort study was conducted to assess second-line treatment initiation and treatment delay amo
259 rinotecan with or without bevacizumab in the second-line treatment of metastatic colorectal cancer.
260 added to systemic therapy in the first- and second-line treatment of patients with colorectal liver
261 ce exists to support the use of nivolumab as second-line treatment of patients with squamous advanced
262 ucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.
265 in the post-implementation group initiated a second-line treatment regimen more rapidly than those in
267 cin or levofloxacin within triple therapy as second-line treatment were associated with greater effec
271 servation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pe
273 ffectiveness than bismuth-based therapy as a second-line treatment, while bismuth-based therapy achie
281 hlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative On
282 ed with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly impro
284 ines Agency-should be preferentially used as second-line treatments in these patient populations, typ
285 ecomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity
287 ves should be used (prescribed) as first- or second-line treatments, though a consensus agreed that b
293 As; and (3) effects on OS were much lower in second-line trials (median [interquartile range] respons
297 by another arm to compare first-line versus second-line use of bevacizumab on progression, performed
299 us (low risk vs high risk), line of therapy (second line vs third line), and anatomic site (pleural v
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。